Palisades Investment Partners LLC Has $6.34 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Palisades Investment Partners LLC raised its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 9.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,479 shares of the company's stock after acquiring an additional 3,436 shares during the period. Krystal Biotech makes up 2.7% of Palisades Investment Partners LLC's portfolio, making the stock its 15th biggest holding. Palisades Investment Partners LLC owned approximately 0.14% of Krystal Biotech worth $6,341,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. FMR LLC boosted its holdings in Krystal Biotech by 0.5% during the fourth quarter. FMR LLC now owns 4,314,014 shares of the company's stock valued at $675,833,000 after acquiring an additional 21,133 shares during the period. Vanguard Group Inc. boosted its holdings in Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after acquiring an additional 28,707 shares during the period. Avoro Capital Advisors LLC boosted its holdings in Krystal Biotech by 0.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock valued at $411,831,000 after acquiring an additional 6,600 shares during the period. Hood River Capital Management LLC boosted its holdings in Krystal Biotech by 2.1% during the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after acquiring an additional 10,622 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Krystal Biotech by 16.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after buying an additional 71,200 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on KRYS shares. Chardan Capital reiterated a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday, May 7th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. HC Wainwright reiterated a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research note on Tuesday, May 6th. Guggenheim reduced their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Citigroup reduced their target price on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research note on Friday, May 16th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $211.13.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This trade represents a 1.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by company insiders.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS traded up $1.89 during mid-day trading on Tuesday, hitting $126.94. 63,407 shares of the stock were exchanged, compared to its average volume of 307,640. The company has a market cap of $3.67 billion, a P/E ratio of 42.38 and a beta of 0.79. The stock's fifty day simple moving average is $160.06 and its two-hundred day simple moving average is $166.27. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).